Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Entrada Therapeutics Inc (NASDAQ: TRDA) closed the day trading at $5.95 up 2.06% from the previous closing price of $5.83. In other words, the price has increased by $2.06 from its previous closing price. On the day, 0.56 million shares were traded. TRDA stock price reached its highest trading level at $5.98 during the session, while it also had its lowest trading level at $4.9801.
Ratios:
For a better understanding of TRDA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 18.64 and its Current Ratio is at 18.64. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, ROTH MKM on December 06, 2024, initiated with a Buy rating and assigned the stock a target price of $29.
On January 05, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $22.
On April 03, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $25.H.C. Wainwright initiated its Buy rating on April 03, 2023, with a $25 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 09 ’25 when PARMAR KUSH sold 27,000 shares for $7.50 per share. The transaction valued at 202,554 led to the insider holds 1,093,313 shares of the business.
5AM Ventures V, L.P. sold 20,065 shares of TRDA for $150,528 on Jul 09 ’25. The 10% Owner now owns 3,163,066 shares after completing the transaction at $7.50 per share. On Jul 09 ’25, another insider, 5AM Ventures V, L.P., who serves as the 10% Owner of the company, sold 6,935 shares for $7.50 each. As a result, the insider received 52,026 and left with 1,093,313 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRDA now has a Market Capitalization of 225822720 and an Enterprise Value of -119971768. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.84 while its Price-to-Book (P/B) ratio in mrq is 0.60. Its current Enterprise Value per Revenue stands at -0.697 whereas that against EBITDA is -15.2.
Stock Price History:
The Beta on a monthly basis for TRDA is -0.13, which has changed by -0.58823526 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, TRDA has reached a high of $21.79, while it has fallen to a 52-week low of $5.62. The 50-Day Moving Average of the stock is -15.30%, while the 200-Day Moving Average is calculated to be -49.89%.
Shares Statistics:
Over the past 3-months, TRDA traded about 159.41K shares per day on average, while over the past 10 days, TRDA traded about 265920 shares per day. A total of 38.03M shares are outstanding, with a floating share count of 22.36M. Insiders hold about 41.08% of the company’s shares, while institutions hold 53.05% stake in the company. Shares short for TRDA as of 1752537600 were 1297778 with a Short Ratio of 8.14, compared to 1749772800 on 1102626. Therefore, it implies a Short% of Shares Outstanding of 1297778 and a Short% of Float of 6.3200004000000005.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating for Entrada Therapeutics Inc (TRDA) is a result of the insights provided by 1.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.78, with high estimates of -$0.78 and low estimates of -$0.78.
Analysts are recommending an EPS of between -$3.13 and -$3.13 for the fiscal current year, implying an average EPS of -$3.13. EPS for the following year is -$4.32, with 3.0 analysts recommending between -$3.44 and -$5.1.
Revenue Estimates
3 analysts predict $7.83M in revenue for the current quarter. It ranges from a high estimate of $12M to a low estimate of $4.5M. As of the current estimate, Entrada Therapeutics Inc’s year-ago sales were $19.57MFor the next quarter, 3 analysts are estimating revenue of $4.83M. There is a high estimate of $6M for the next quarter, whereas the lowest estimate is $4M.
A total of 1 analysts have provided revenue estimates for TRDA’s current fiscal year. The highest revenue estimate was $50.72M, while the lowest revenue estimate was $50.72M, resulting in an average revenue estimate of $50.72M. In the same quarter a year ago, actual revenue was $210.78M
